Mirum Pharmaceuticals prepares new brelovitug, volixibat and LIVMARLI data for AASLD 2026
Mirum Pharmaceuticals will present additional evidence across three rare liver disease programmes at The Liver Meeting 2026. Already disclosed results include significant responses in the brelovitug AZURE-1 trial and volixibat VISTAS study, while longer-term and subgroup analyses may clarify safety, symptom improvement and regulatory prospects.
